The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle - Full Text View

Purpose

We intend to use repetitive magnetic stimulation to the quadriceps muscle to try to improve strength and improve the metabolic function of the muscle.

Condition	Intervention
Chronic Obstructive Pulmonary Disease	Device: Repetitive magnetic stimulation to the quadriceps

MedlinePlus related topics:

COPD (Chronic Obstructive Pulmonary Disease)

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Efficacy Study

Official Title:	The Use of Repetitive Magnetic Stimulation for Strength Training of the Quadriceps Muscle in Patients With Chronic Obstructive Pulmonary Disease

Further study details as provided by Imperial College London:

Primary Outcome Measures:

Quadriceps Twitch force

Secondary Outcome Measures:

Quadriceps maximal voluntary contraction, Oxidative enzyme profile, fibre type distribution and capillarity of the muscle, quality of life questionnaires

Estimated Enrollment:	20
Study Start Date:	January 2005
Study Completion Date:	February 2006
Primary Completion Date:	February 2006 (Final data collection date for primary outcome measure)

Detailed Description:

Quadriceps strength is reduced in COPD. Increasing quadriceps strength is one of the goals of pulmonary rehabilitation yet some patients with severe COPD are unable to exercise with sufficient intensity, due to breathlessness, to achieve a true training benefit.

Transcutaneous electrical stimulation of the femoral nerve has been shown to improve quadriceps muscle strength, muscle mass, and performance in patients with severe COPD. Magnetic stimulation may be preferred because it offers the opportunity to train the whole muscle and because it is painless. In this pilot study we are investigating whether repetitive magnetic stimulation camn increase the strength of the quadriceps muscle and whether it confers any change in structure or metabolism of the muscle itself.

Eligibility

Ages Eligible for Study:	40 Years to 85 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Chronic Obstructive Pulmonary Disease

Exclusion Criteria:

Aspirin therapy Cardiac Pacemaker

-

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00159367

Locations


United Kingdom
	Royal Brompton Hospital
	London, United Kingdom, Sw3 6NP

Sponsors and Collaborators

Imperial College London

Magstim Company, Whitland, Wales

Investigators


Principal Investigator:	Michael I Polkey, PhD	Imperial College London

More Information

Responsible Party:	Royal brompton Hospital/Imperial College ( Professor Michael I Polkey )
Study ID Numbers:	RR1, EU QLRT-2001-2285
First Received:	September 9, 2005
Last Updated:	August 18, 2008
ClinicalTrials.gov Identifier:	NCT00159367
Health Authority:	United Kingdom: Research Ethics Committee

Keywords provided by Imperial College London:

Neuromuscular electrical stimulation

Study placed in the following topic categories:

Lung Diseases, Obstructive

Respiratory Tract Diseases

Lung Diseases

Pulmonary Disease, Chronic Obstructive

ClinicalTrials.gov processed this record on September 05, 2008

Sponsors and Collaborators:	Imperial College London Magstim Company, Whitland, Wales
Information provided by:	Imperial College London
ClinicalTrials.gov Identifier:	NCT00159367